Biotechnology industries
The Techcenter@UMBC Incubator Program has welcomed a new biotechnology start-up, Lentigen Corp, which aims to revolutionize gene therapy by delivering genetic material into cells to cure genetic disorders. Lentigen's chief executive officer, Boro Dropulic, explained that gene therapy allows doctors and scientists to target the causes of
Biotechnology industries
Aastrom Biosciences, Inc. (ASTM), a leader in the development of patient-specific products for tissue repair and regeneration, has announced its inclusion in the Russell 3000 Index. This significant milestone for the company marks its recognition as one of the 3,000 largest U.S. companies based on total market capitalization.
Biotechnology industries
As larger pharmaceutical companies retreat from the hospital antibiotics market, smaller companies like Cubist, Vicuron, Basilea, and Novexel are positioned to establish niches in this arena. Decision Resources, Inc., reports that large pharmaceutical companies, such as Roche, Wyeth, Pfizer, Johnson & Johnson, Merck, and GlaxoSmithKline, have dominated the market but
Biotechnology industries
MDS Nordion and Macrocyclics Inc. have announced a three-year research and development collaboration to develop innovative bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals. This partnership aims to create novel chelate structures, linkers, and conjugation methods that will enable researchers to use a wider range of targeting
Biotechnology industries
Advanced Viral Research Corp. (ADVR) has successfully secured patent #ZL 00811493.5 in China for its flagship product AVR118, a biopolymer with novel immunomodulatory activity. This patent, titled "Preparation of a Therapeutic Composition," complements ADVR's existing intellectual property estate and provides additional protection for AVR118. The
Biotechnology industries
LifeCycle Pharma A/S, a privately owned biotechnology company, has completed a EUR 15 million private placement, led by Alta Partners, a US-based life science investor. The funding will be used to advance the company's main projects from the clinical phase to registration, including reformulated versions of fenofibrate
Biotechnology industries
In a significant step towards developing innovative treatments for life-threatening diseases, InNexus Biotechnology, Inc. has partnered with the renowned Mayo Clinic in a multiyear collaborative research agreement. This collaboration aims to drive the leading science of monoclonal antibody development, focusing on cancer, cardiovascular disease, and other challenging conditions. By combining
Biotechnology industries
Pennsylvania Governor Edward G. Rendell announced the sixth grant from the $5 million Manufacturing Sector Incumbent Worker Training Program, allocating $400,000 to upgrade the skills of workers in biotech companies in southeast Pennsylvania. The investment aims to secure the biotech industry in the region by ensuring workers are among
Biotechnology industries
RheoGene Inc. has revolutionized the field of gene-targeting enzymes with the introduction of AttSite Recombinases, a novel platform that enables site-specific DNA modification in a broad range of organisms. This innovative technology has far-reaching applications in functional genomics, transgenics technology, biotherapeutic protein production, and stem cell and gene therapy. Thomas
Biotechnology industries
Biogen Idec, the world's third-largest biotechnology company, has partnered with Ciber, Inc. for a multi-year contract to provide day-to-day maintenance and application development services for its Lotus Notes application. The partnership leverages Ciber's global delivery model, offering a cost-effective and high-quality delivery option. The contract marks
Biotechnology industries
Biotie Therapies Corp. aims to bolster its financial standing by offering new shares primarily to existing shareholders, option right holders, and convertible loan holders, with the hope of raising up to approximately EUR 9 million in new capital. The proposed share capital increase involves issuing a maximum of 12 million
Biotechnology industries
ViroLogic, Inc., a biotechnology company, has achieved a record revenue of $10 million in the first quarter of 2005, marking a significant increase from the $9 million revenue reported in the same quarter of 2004. The company's HIV patient testing products generated $5.9 million in revenue, while
